Figure 2

The correlation between EGFR mutation type and prognosis in lung cancer. (A) Kaplan-Meier estimates of progression-free survival of patients harboring exon 19 deletions (black) and L858R mutation (red) who had received gefitinib treatment. Median survival time of patients harboring exon 19 deletions (black) and L858R mutation (red) was 14.6 months and 13.1 months, respectively. The difference was not statistically significant (p = 0.78). (B) Kaplan-Meier estimates of overall survival of patients harboring exon 19 deletions (black) and L858R mutation (red) who had received gefitinib treatment. Median survival time of patients harboring exon 19 deletions (black) and L858R mutation (red) was 31.1 months and 15.3 months, respectively. The difference was not statistically significant (p = 0.29).